Skip to main content
. 2019 Jul 24;2(7):e197621. doi: 10.1001/jamanetworkopen.2019.7621

Figure 4. Early Changes in Interleukin 1 Receptor Antagonist (IL-1RA) and Brain-Derived Neurotrophic Factor (BDNF) Levels and Progression-Free Survival (PFS) in Patients With Gastrointestinal Tract Cancer.

Figure 4.

CRC indicates colorectal cancer; dMMR, DNA mismatch repair deficiency; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; MSI-H, microsatellite instability–high; MSS, microsatellite stable; and PD-L1, programmed cell death ligand 1.

aOf 56 patients, 1 patient had no change to IL-1RA levels.